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Abstract
Background: Previous studies have demonstrated that hepatitis B virus (HBV) infection increases the risk for ALT elevations
in HIV-HBV co-infected patients during the first year of HAART; however, there is limited data on the prevalence of ALT
elevations with prolonged HAART in this patient group.
Methods/Principal findings: To identify factors associated with ALT elevations in an HIV-HBV co-infected cohort receiving
prolonged HAART, data from 143 co-infected patients on HAART enrolled in an international HIV-HBV co-infected cohort
where ALT measurements were obtained every 6 months was analysed. A person-visit analysis was used to determine
frequency of ALT elevation ($2.56ULN) at each visit. Factors associated with ALT elevation were determined using
multivariate logistic regression with generalized estimating equations to account for correlated data. The median time on
HAART at the end of follow-up was 5.6 years (range 0.4–13.3) years. During follow-up, median ALT was 36 U/L with 10.6% of
person-visits classified as having ALT elevation. Most ALT elevations were grade 2 (86.5%), with only 13.5% of all ALT
elevations grade 3 or higher. Univariate associations with ALT elevation (p,0.05) included history of AIDS, HBV DNA
$2,000 IU/ml, HBeAg positive, study visit CD4 ,200 cells/ml and nadir CD4 ,200 cells/ml. In the multivariate analysis, only
study visit CD4 ,200 cells/ml (OR 2.07, 95%CI 1.04–4.11, p=0.04) and HBeAg positive status (OR 2.22, 95%CI 1.03–4.79,
p=0.04) were independently associated with ALT elevation.
Conclusions: In this HIV-HBV co-infected cohort, elevated ALT after .1 year of HAART was uncommon, and severe ALT
elevations were rare. HIV-HBV co-infected patients on long-term HAART who are either HBeAg positive or have a CD4 count
of ,200 cells/ml are at increased risk for ALT elevations.
Citation: Audsley J, Seaberg EC, Sasadeusz J, Matthews GV, Avihingsanon A, et al. (2011) Factors Associated with Elevated ALT in an International HIV/HBV Co-
Infected Cohort on Long-Term HAART. PLoS ONE 6(11): e26482. doi:10.1371/journal.pone.0026482
Editor: Zhiwei Chen, The University of Hong Kong, Hong Kong
Received June 7, 2011; Accepted September 27, 2011; Published November , 2011
Copyright:  2011 Audsley et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors acknowledge funding from the National Institutes of Health RO1 A1060449. Some of the data in this manuscript were collected by the
Multicenter AIDS Cohort Study (MACS) with centres (Principal Investigators) at The Johns Hopkins Bloomberg School of Public Health (Joseph B. Margolick, Lisa P.
Jacobson), Howard Brown Health Center, Feinberg School of Medicine, Northwestern University, and Cook County Bureau of Health Services (John P. Phair, Steven
M. Wolinsky), University of California, Los Angeles (Roger Detels), and University of Pittsburgh (Charles R. Rinaldo). The MACS is funded by the National Institute of
Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute, grants UO1-AI-35042, UL1-RR025005 (GCRC), UO1-AI-
35043, UO1-AI-35039, UO1-AI-35040, and UO1-AI-35041. JA is a Nation Health and Medical Research Council (NHMRC) Clinical Research Training Fellow and SRL is
an NHMRC Practitioner Fellow. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist. Please note that Taylor9s Square Private Clinic (TSPC), Sydney, Australia is
not a company; it is a privately-run general practitioners9 clinic that specializes in sexual health medicine. Some patients in the study were recruited from this
clinic, and they attended TSPC for their study visits.
* E-mail: jennifer.audsley@monash.edu
Introduction
Approximately 33 million people are infected with human
immunodeficiency virus (HIV) [1]. HIV-hepatitis B virus (HBV)
co-infection is common due to shared routes of transmission, with
reported figures indicating that 6–9% of HIV-infected individuals
in developed countries and in Asia are chronically infected with
HBV [2–4]. HIV infection has a significant impact on the natural
history of HBV infection, with increased levels of HBV DNA and
an elevated risk of liver-associated mortality [5–6].
Co-infection with HBV clearly increases the risk for an elevated
alanine aminotransferase (ALT) in patients on HAART [7]. The
protease inhibitors are all associated with increased ALT, with
high dose ritonavir posing the greatest risk [8]. Non-nucleoside
reverse transcriptase inhibitors (NNRTI) have also been linked to
hepatotoxicity, particularly nevirapine as part of a hypersensitivity
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26482
1syndrome [9]. The nucleoside reverse transcriptase inhibitors
(NRTIs) have the lowest risk but are associated with liver toxicity
from steatohepatitis and mitochondrial toxicity [10]. Immune
reconstitution has also been recognized as a possible risk factor for
elevated ALT following initiation of HAART [11–12]. Another
contributing factor may be withdrawal of lamivudine (LMV)
therapy and/or the development of LMV resistance leading to
enhanced replication of HBV [13–14]. Finally, immune escape
mutants of HBV, including mutations that reduce synthesis of
HBeAg or pre-core mutants, may be selected causing progressive
liver damage [12].
With prolonged exposure to HAART, HIV-HBV co-infected
patients may have an increasing risk of ALT elevations due to
longer duration of hepatotoxic drugs and an increased immune
response to HBV antigens. Alternatively, the risk may decrease
with longer HAART especially if HBV-active drugs effectively
control HBV replication. In order to determine the factors
associated with elevated ALT among HIV-HBV co-infected
patients on HAART longer than one year, we studied a
prospectively-followed international cohort of HIV-HBV co-
infected patients.
Materials and Methods
Ethics statement
Written, informed consent was obtained from all participants,
and the study was approved by the relevant Human Research
Ethics Committees in Australia, the United States and Thailand.
This study was conducted according to the principles expressed in
the Declaration of Helsinki.
Study participants
169 HIV/HBV co-infected individuals were enrolled from sites
in Australia (The Alfred Hospital, The Royal Melbourne Hospital
and Melbourne Sexual Health Clinic, Melbourne; St Vincent’s
Hospital and Taylor’s Square Clinic, Sydney); the United States
(The Multicenter AIDS Cohort Study - MACS) and in Thailand
(HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok)
over the period October 2004 to February 2008. Eligibility criteria
have been previously reported [15]. Individuals with chronic
hepatitis C virus (HCV; HCV antibody and HCV RNA positive at
study entry) were not eligible. For inclusion in this analysis, we
selected only those time points at which a patient was on HAART,
had a positive HBsAg and had ALT assessed. Thus, this study
included 701 person-visits from 143 patients.
Data abstraction and collection
Clinical and laboratory data were collected or abstracted from
medical records at study entry and at 6-monthly follow-up visits.
Clinical data included demographics, prior and current anti-HIV
and anti-HBV therapy, previous/present AIDS-defining illnesses,
history/current jaundice, hepatocellular carcinoma (HCC), asci-
tes, oesophageal varices, hepatic encephalopathy and Child-Pugh
stage. Laboratory measurements included ALT, aspartate amino-
transferase (AST), international normalized ratio (INR) or
prothrombin time, haemoglobin, white blood cell count, platelets,
hepatitis B e antigen (HBeAg), HBe antibody (anti-HBe), HB
surface antibody (anti-HBs), HIV RNA, CD4 count at the time of
study visit, and nadir CD4 count. Hepatitis delta virus (HDV) was
collected at study entry only. Data on alcohol intake and
compliance to HAART were also collected at each visit. Patients
in the US and Australia accrued up to four years of follow-up and
those from Thailand up to 18 months.
Laboratory testing
HBV DNA was quantified using the RealART
TM HBV LC
PCR (QIAGEN), lower limit of detection (LLOD) 20 IU/ml, in
accordance with the manufacturer’s instructions.
HIV RNA was quantified by the approved, standard test used at
each site, which were performed according to manufacturer’s
instructions. For analysis, HIV RNA was classified as detectable
($400 copies/ml) or undetectable (,400 copies/ml).
Statistical analysis
This longitudinal study included data from up to 9 visits for
each participant. At each study visit elevated ALT was defined
using the ACTG criteria: grade 0 (,1.256upper limit of normal,
ULN); grade 1 (1.25–2.56ULN); grade 2 (.2.5–5.06ULN); grade
3( .5.0–10.06ULN); and grade 4 (.10.06ULN)) where ALT
ULN was set at 30 U/L for men and 19 U/L for women based on
Prati et al [16]. Clinical and laboratory variables examined in the
analyses included study visit, recruitment site, gender, age .40
years, injecting drug use (IDU) at study entry, men who have sex
with men (MSM) contact, heterosexual contact, previous AIDS-
defining illness, HBV DNA $2000 IU/ml, HBeAg status, anti-
HBe status, HBV-active antiretrovirals (ARVs), duration on
HAART, current ARVs, detectable HIV RNA (.400 copies/
ml), current and nadir CD4 cell count, median weekly alcohol
intake and the components of the Child-Pugh score. The HBV
DNA cut-off used in this analysis was $2,000 IU/ml since it had
previously been shown to be associated with ALT elevation in the
first 18 months of HAART [17].
Standard descriptive statistics (e.g., frequency, percentages) were
used to characterize the study cohort at study entry. The
prevalence and cumulative incidence of grade 2 or higher ALT
elevation and the change in median ALT over time were displayed
graphically. Multiple logistic regression with robust variance
estimation was used to determine characteristics associated with
ALT elevations of grade 2 or higher while accounting for within-
subject correlation [18]. To account for the prospective study
design and the fundamental differences between the cohorts, we
forced covariates for study visit, study site and gender into all
multivariate models. Observations with missing data were
included in the multiple regression analyses using multiple
imputation [19]. All statistical analyses were performed using
SAS 9.2 (SAS Institute, Cary, NC), and statistical significance was
defined as a p-value ,0.05.
Results
Baseline characteristics of study subjects
The majority of the cohort was male (90.2%), aged over 40 years
(62.9%)andwithaHIVriskfactorofMSM(71.3%),assummarized
in Table 1. HBV DNA was detected in 21.0% and HIV RNA was
detected in 15.8% of patients. About half the cohort was HBeAg
positive (50.8%). The median time on HAART since HAART
initiation at enrolment to this study and at the end of follow-up was
3.5 yrs (range: 0.3–10.8 yrs) and 5.6 (0.4 to 13.3) years respectively.
Sixty-two percent of the patients were receiving a non-nucleoside
reverse transcriptase inhibitor and 38% a protease inhibitor.
Ninety-three per cent of those on HAART had HBV-active agents
as part of their HAART regimen, which included lamivudine
(LMV) or emtricitabine (FTC; 18.2%), tenofovir disoproxil
fumarate (TDF; 13.3%) and TDF with LMV or FTC (61.5%).
Baseline CD4 was ,200 cells/ml in a minority of cases (16.5%) with
a medianCD4count of389cells/ml. Themajorityofthecohorthad
a mean alcohol intake of ,14 standard drinks/week (92.8%) and a
Childs-Pugh score of 5 (88.9%).
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Across the 701 person-visits, the median ALT was 36 (IQR 26–
50) and notably, it remained relatively stable throughout follow-up
(Figure 1). Only 74 person-visits (10.6%) were classified as having
grade 2 or higher ALT elevation of which the majority were grade
2 (86.5%, n=64) and grade 3 and 4 elevations occurred in 10.8%
(n=8) and 2.7% (n=2) of visits, respectively. The probability of a
grade 2 or higher ALT elevation remained stable about 10%
throughout follow-up (Figure 2). The cumulative incidence
reached 33% by the end of the study period (Figure 2). In
contrast the cumulative incidence of grade 3 or higher elevation
was low at 8.7% (data not shown).
The majority of the ALT elevations (78.4%) were in patients
who had more than one visit with grade 2 or higher ALT
elevation. Three of these patients had elevated ALT for at least 2
years (5 consecutive study visits). We were unable to determine if
these persistent elevations of ALT were associated with adverse
outcomes.
There was no association between elevated ALT and anti-HBe
seroconversion. Anti-HBe seroconversion was observed in a total
of 10 patients but elevated ALT was observed prior to anti-HBe
seroconversion in only one patient. In this patient, ALT elevation
continued following seroconversion. In the other 9 patients, there
was no change in ALT either prior to or following anti HBe
seroconversion
Univariate analysis (Table 2) identified that a history of AIDS-
related illness, HBV DNA .2,000 IU/ml, HBeAg positive status,
CD4 count ,200 cells/ml, and a nadir CD4 count ,200 cells/ml
were significantly associated with ALT elevation. Notably,
HAART duration longer than 1 year was not associated with
risk of ALT elevation. In the multivariate analysis only CD4 count
,200 cells/ml (OR 2.07, p=0.04) and HBeAg positive status (OR
2.22, p=0.04) remained independently associated with increased
risk for elevated ALT (Table 3).
Discussion
This study is the first designed to specifically examine ALT
elevations in a large, long-term cohort of HIV-HBV co-infected
patients on .1 year of HAART. We found that in patients on
HAART for a median time of over 5years, ALT remained
relatively stable, the probability of ALT elevations was low and did
not increase over time and most ALT elevations were accounted
for by patients with more than one episode of ALT elevation. The
estimated cumulative incidence of grade 2 or higher ALT
elevations was 33% over 4 years and for grade 3 or higher was
only 8.7%. Patients with more advanced HIV (follow-up visit CD4
count ,200cells/ml) and those who were HBeAg positive were at
the greatest risk for ALT elevations on long-term HAART.
Elevated ALT is generally regarded as a marker of hepatic
necrosis and inflammation, although liver damage may be present
with normal ALT [5,20]. It is encouraging that ALT elevations in
HIV-HBV co-infected patients on HAART over several years was
low and did not increase with duration of HAART. Only three
patients had elevated ALT for a prolonged period (at least 2 years).
Several observational cohort studies have shown that the incidence
of ALT elevations on HAART ranged from 5–45%, and varied
based on the definition used including any elevation above
normal, mild elevation (up to and including Grade 2 i.e. .2.5–
56ULN) and severe elevation (Grade 3 .5,106and/or Grade 4
.106ULN). In addition, most published observational cohort
studies of patients with hepatitis co-infection have included both
HCV and HBV co-infection with a higher percentage of patients
co-infected with HCV than HBV [7–8,17,21–31]. Follow up in
these studies ranged from 6 months to 4.8 years (median 17.8
months) and common factors associated with ALT elevations
included ritonavir or nevirapine-containing regimens and baseline
ALT [8,25–27,31–32]. These studies concentrated on either
treatment-naı ¨ve patients commencing HAART or PI-naı ¨ve
patients commencing PI-containing regimens, and suggested that
the highest risk of elevated ALT was early following initiation of
HAART. In contrast, in our study 94.4% of patients had been
Table 1. Study entry demographics and clinical
characteristics.
Characteristic Number (%)
Participants by location (n=143)
Australia 61 (42.7)
MACS 39 (27.3)
Thailand 43 (30.0)
Gender,m
1/f 129 (90.2)/14 (9.8)
Age .40 years 90 (62.9)
2HIV risk factor
Ever IDU 15 (10.7)
Heterosexual contact 32 (22.4)
MSM contact 102 (71.3)
History of AIDS 53 (37.1)
HBeAg status, positive/negative (n=134) 68 (50.8)/66 (49.2)
Anti-HBe status, positive/negative (n=103) 42 (40.8)/61 (59.2)
Detectable HBV DNA ($2,000 IU/ml) (n=138) 29 (21.0)
Detectable HIV RNA ($400 copies/ml) (n=139) 22 (15.8)
Study entry CD4 ,200 cells/ml (n=138) 23 (16.5)
Nadir CD4 ,200 cells/ml (n=141) 88 (62.4)
Child-Pugh score (n=117)
5 104 (88.9)
6 10 (8.6)
7–9 3 (2.6)
Alcohol intake (mean drinks/week) (n=140)
none 45 (32.1)
,14 85 (60.7)
$14 10 (7.1)
Current ARVs
NRTI 137 (95.8)
PI 54 (37.8)
NNRTI 89 (62.2)
HBV-active ARVs 133 (93.0)
HBV active HAART
None 10 (7.0)
LMV/FTC only 26 (18.2)
TDF only 19 (13.3)
TDF+LMV/FTC 88 (61.5)
1for analysis, male category includes 1 transgender M-.F individual.
2some participants report multiple risk factors.
MACS: Multicenter AIDS Cohort Study; IDU: intravenous drug use; ARV:
antiretroviral agent; HAART: highly active antiretroviral therapy; MSM: men who
have sex with men; HBeAg/Ab: hepatitis B e antigen/antibody; NRTI: nucleoside
reverse transcriptase inhibitor; PI: protease inhibitor; NNRTI: non-nucleoside
reverse transcriptase inhibitor; LMV: lamivudine; FTC: emtricitabine; TDF:
tenofovir disoproxil fumurate.
doi:10.1371/journal.pone.0026482.t001
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published observational cohort describing liver disease included
only HIV-HBV co-infected patients and reported that patients
with mean transaminases above the ULN were significantly more
likely to develop advanced liver disease [29].
A significant association between lower CD4 count and elevated
ALT has not been consistently reported in previous studies. In one
study of patients with HIV-HBV co-infection there was no
significant association between mean CD4 count during follow up
and the development of advanced liver disease [29], while
Sulkowski et al. reported that a larger CD4 cell count increase
was associated with severe hepatotoxicity (ALT .56ULN) in
HIV-hepatitis co-infection [7]. In studies of HIV mono-infected
patients that exclude viral hepatitis, one study has reported an
increased risk of ALT with lower CD4 while another study
reported the opposite findings [33–34]. We were surprised to find
this association in the setting of HIV-HBV co-infection given our
previous work showing that in HIV-HBV co-infected patients not
receiving HAART, a lower CD4 count was associated with a
lower number of HBV-specific T-cells [35] and that there was little
increase in HBV-specific T-cells in the first 48 weeks following
HBV-active HAART [11]. However, elevated ALT can occur
secondary to both the adaptive and innate immune responses
(summarised in [36]). It is possible that other factors might be
driving an increase in ALT, even in patients with well controlled
HBV DNA, such as circulating lipopolysaccharide (LPS) in HIV-
infected patients which is higher in patients with low CD4 T-cell
counts [37–38]. Elevated LPS can increase Kupffer cell activation
[39], leading to liver disease progression as described in HCV
infection, HIV-HCV co-infection and alcoholic liver disease [40–
42] and we have recently demonstrated that LPS is also
significantly elevated in HIV-HBV co-infection [43].
HBeAg positive status represents greater HBV replication and is
considered a surrogate marker of elevated HBV DNA in untreated
patients. HBV DNA is usually higher in HBeAg positive than in
HBeAg negative disease [44]. Rates of HBeAg loss and/or
Figure 1. Median ALT data summary by person-visits over the study duration.
doi:10.1371/journal.pone.0026482.g001
Figure 2. Prevalence and cumulative incidence of grade 2 or higher ALT elevation during the study period.
doi:10.1371/journal.pone.0026482.g002
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setting of prolonged suppression of HBV DNA [45–46]. In this
study, both HBeAg positive status and HBV DNA $2,000 IU/ml
were significantly associated with elevated ALT at the univariate
level, however only HBeAg status remained significant when both
HBeAg and HBV DNA were included in the multivariate model.
These findings may be explained by the low number of patients
with HBV DNA above 2,000 IU/ml (15%) compared with almost
half the cohort (45%) being HBeAg positive over the follow-up
period. HBeAg could also be a surrogate for duration of infection
with HBV, a variable we were unable to collect in this cohort. In
general, patients who are HBeAg positive are infected for a shorter
duration of time than those who are HBeAg negative [47] and are
therefore more likely to enter an immunoactive phase which may
contribute to an elevated ALT.
There are several limitations to this study. First, it is possible we
may have underestimated the prevalence of an elevated ALT in
our cohort as patients only had ALT collected every 6 months.
There were 182 person-visits excluded from the analysis due to
missing ALT data. However, we think this was unlikely to have
Table 2. Associations of selected cohort characteristics with elevated ALT
1.
Variable All follow-up
Person-visit, n (%) Median ALT IQR %elevated ALT
1 p
History of AIDS Yes 252 (36.0) 43 27–61 17.1% 0.04
No 599 (85.4) 34 25–46 6.9
HBV DNA $2,000 IU 92 (15.1) 44 34–64 17.4 0.01
,2,000 IU 519 (84.9) 35 25–49 9.4
HBeAg Positive 299 (45.3) 41 30–58 15.1 0.001
Negative 361 (54.7) 33 24–45 7.5
HBV-active ARVs None 14 (2.0) 44 30–84 28.6 0.3
LMV/FTC only 102 (14.6) 40 27–52 13.7
TDF only 61 (8.7) 31 25–46 4.9
TDF+LMV/FTC 524 (74.8) 35 25–50 10.7
Current NRTI Yes 692 (98.7) 36 26–60 10.3 0.14
No 9 (1.3) 43 34–90 33.3
Current PI Yes 340 (48.5) 35 25–49 12.9 0.20
No 361 (51.5) 38 27–50 8.3
Current NNRTI Yes 390 (55.6) 38 22–49 8.5 0.09
No 311 (44.4) 35 25–52 13.2
Alcohol intake
2 None 212 (30.5) 38 27–51 9.4 0.75
,14 std drinks 442 (63.6) 35 25–49 10.2
$14 std drinks 41 (5.9) 43 25–66 22.0
CD4 - study visit ,200 cells/ml 100 (14.5) 42 27–66 20.0 0.002
$200 cells/ml 591 (85.5) 35 25–49 9.1 0.03
Nadir CD4 ,200 cells/ml 412 (60.0) 38 26–55 13.8
$200 cells/ml 275 (40.0) 34 25–44 4.4
Child-Pugh score 5 506 (87.1) 37 26–49 9.9 0.15
6 46 (7.9) 43 29–77 28.3
7–9 29 (5.0) 37 27–46 10.3
1Grade 2 or higher (ACTG criteria), ULN of ALT was 30 for men and 19 for women.
2median weekly standard drinks.
IDU: intravenous drug use; ARV: antiretroviral; HAART: highly active antiretroviral therapy; HBeAg/Ab: hepatitis B e antigen/antibody; LMV: lamivudine; TDF: tenofovir
disoproxil fumarate; FTC: emtricitabine.
Additional variables analysed at the univariate level that were not statistically significant included: recruitment site location, gender, study visit, ever IDU, MSM contact,
heterosexual contact, anti-HBe status, and detectable HIV RNA.
doi:10.1371/journal.pone.0026482.t002
Table 3. Multiple regression analysis – logistic regression
(outcome elevated ALT).
Multivariate Model
Co-variate OR 95% CI p
Study visit 0.95 0.86–1.05 0.35
MACS vs. Thai site 1.29 0.33–5.0 0.72
Australia vs. Thai site 2.03 0.60–6.9 0.26
Female 2.00 0.40–10.1 0.40
HBe Ag positive 2.22 1.03–4.79 0.04
HBV DNA $2,000 IU/ml 2.02 0.84–4.83 0.11
CD4 ,200 cells/ml at time
of study visit
2.07 1.04–4.11 0.04
HBeAg: hepatitis B e antigen.
doi:10.1371/journal.pone.0026482.t003
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sample size. Second, our use of the revised more stringent
guidelines for defining normal ALT may have increased the
prevalence of an elevated ALT; however, we considered that this
definition was appropriate given that previous studies showed ALT
levels are lower in co-infection even in the setting of liver disease
[6] and that they are the currently accepted normal levels of ALT
in patients with HBV mono-infection [AASLD guidelines [48]].
Third, we did not measure HCV RNA or HDV Ab or RNA
throughout follow up. Given the high frequency of MSM in this
cohort, acute HCV could be a possible explanation of elevated
ALT, although we have no evidence for this. In contrast, there is a
low prevalence of HDV infection in Australia and Thailand ([49–
50]; personal communication, Scott Bowden, Victorian Infectious
Diseases Reference Laboratory) so we think this would be an
unlikely cause of elevated ALT. Fourth, we recruited patients from
three geographically different sites; therefore the HBV genotype
distribution and ethnicity were different; however, recruitment site
was not a significant factor in any of the analyses. Finally, we did
not directly assess liver disease severity, other than the Childs-Pugh
scores. The Childs-Pugh scores for the cohort ranged from 5–7
throughout follow-up, which is indicative of relatively mild liver
disease in the cohort, and therefore our results might not be
applicable to cohorts with more advanced liver disease.
In conclusion, in a large prospective cohort of HIV-HBV co-
infected patients on HAART for up to 13.3 years at the end of
follow up, the prevalence of elevated ALT was low and was stable
across study visits. CD4 count ,200 cells/ml and HBeAg positive
status were significantly associated with an increased risk of
elevated ALT; thus HIV-HBV co-infected patients with these
characteristics require careful monitoring of ALT.
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